Review



40780es20 acyclovir acv medchemexpress  (MedChemExpress)


Bioz Verified Symbol MedChemExpress is a verified supplier
Bioz Manufacturer Symbol MedChemExpress manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 93

    Structured Review

    MedChemExpress 40780es20 acyclovir acv medchemexpress
    40780es20 Acyclovir Acv Medchemexpress, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 10 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/40780es20 acyclovir acv medchemexpress/product/MedChemExpress
    Average 93 stars, based on 10 article reviews
    40780es20 acyclovir acv medchemexpress - by Bioz Stars, 2026-05
    93/100 stars

    Images



    Similar Products

    93
    MedChemExpress 40780es20 acyclovir acv medchemexpress
    40780es20 Acyclovir Acv Medchemexpress, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/40780es20 acyclovir acv medchemexpress/product/MedChemExpress
    Average 93 stars, based on 1 article reviews
    40780es20 acyclovir acv medchemexpress - by Bioz Stars, 2026-05
    93/100 stars
      Buy from Supplier

    86
    Valeant Pharmaceuticals abs aspiration bypass system ac anterior chamber acv anterior chamber
    Abs Aspiration Bypass System Ac Anterior Chamber Acv Anterior Chamber, supplied by Valeant Pharmaceuticals, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/abs aspiration bypass system ac anterior chamber acv anterior chamber/product/Valeant Pharmaceuticals
    Average 86 stars, based on 1 article reviews
    abs aspiration bypass system ac anterior chamber acv anterior chamber - by Bioz Stars, 2026-05
    86/100 stars
      Buy from Supplier

    86
    Elion Labs acv
    Acv, supplied by Elion Labs, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/acv/product/Elion Labs
    Average 86 stars, based on 1 article reviews
    acv - by Bioz Stars, 2026-05
    86/100 stars
      Buy from Supplier

    86
    Shanghai Yuanye Biotechnology acyclovir acv
    Acyclovir Acv, supplied by Shanghai Yuanye Biotechnology, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/acyclovir acv/product/Shanghai Yuanye Biotechnology
    Average 86 stars, based on 1 article reviews
    acyclovir acv - by Bioz Stars, 2026-05
    86/100 stars
      Buy from Supplier

    96
    DSMZ rch acv
    a , Menin ChIP-seq after 24 h treatment with DMSO or 250 nM Menin inhibitor VTP50469 (MENi) in <t>SEM,</t> <t>RCH-ACV</t> and OCI-AML3 cells. Metaplots show mean reference normalized reads per million (RRPM) centered on transcription start sites (TSS) genome-wide. b , Dose response curves to MENi recorded at 48 h using CellTiterGlo (n = 5 for SEM and RCH-ACV cells, n = 3 for OCI-AML3 cells). c , Colony forming units recorded after culture in Menin inhibitor (n=5). Error bars represent standard error. d , Violin plots depicting the log2 fold changes of differentially expressed genes (FDR < 0.05) after 24 h MENi (250 nM), split by Menin binding at the promoter. e , Upset plot representing the cell lines in which shared Menin-bound genes (centre of Venn diagram in ) are downregulated following MENi (250 nM) for 24 h. f , Intersections of all upregulated genes following 24 h MENi (250 nM) in SEM, OCI-AML3, and RCH-ACV cells. g , Correlation heatmap of genome-wide Menin ChIP-seq signal in cell lines (SEM, RCH-ACV, and OCI-AML3) and Menin ChIPmentation in primary patient samples (NPM1c-AML, iALL28349, iALL863388). h , Heatmaps and metaplots showing the mean Menin signal at promoters in SEM cells (ChIP-seq) and two primary patient samples (ChIPmentation), sorted and k-means clustered by Menin signal in SEM cells. i , Heatmaps and metaplots showing the mean Menin signal at promoters in OCI-AML3 cells (ChIP-seq) and one primary patient sample (ChIPmentation), clustered by Menin signal in OCI-AML3 cells.
    Rch Acv, supplied by DSMZ, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/rch acv/product/DSMZ
    Average 96 stars, based on 1 article reviews
    rch acv - by Bioz Stars, 2026-05
    96/100 stars
      Buy from Supplier

    94
    Elabscience Biotechnology testosterone e el r0389
    a , Menin ChIP-seq after 24 h treatment with DMSO or 250 nM Menin inhibitor VTP50469 (MENi) in <t>SEM,</t> <t>RCH-ACV</t> and OCI-AML3 cells. Metaplots show mean reference normalized reads per million (RRPM) centered on transcription start sites (TSS) genome-wide. b , Dose response curves to MENi recorded at 48 h using CellTiterGlo (n = 5 for SEM and RCH-ACV cells, n = 3 for OCI-AML3 cells). c , Colony forming units recorded after culture in Menin inhibitor (n=5). Error bars represent standard error. d , Violin plots depicting the log2 fold changes of differentially expressed genes (FDR < 0.05) after 24 h MENi (250 nM), split by Menin binding at the promoter. e , Upset plot representing the cell lines in which shared Menin-bound genes (centre of Venn diagram in ) are downregulated following MENi (250 nM) for 24 h. f , Intersections of all upregulated genes following 24 h MENi (250 nM) in SEM, OCI-AML3, and RCH-ACV cells. g , Correlation heatmap of genome-wide Menin ChIP-seq signal in cell lines (SEM, RCH-ACV, and OCI-AML3) and Menin ChIPmentation in primary patient samples (NPM1c-AML, iALL28349, iALL863388). h , Heatmaps and metaplots showing the mean Menin signal at promoters in SEM cells (ChIP-seq) and two primary patient samples (ChIPmentation), sorted and k-means clustered by Menin signal in SEM cells. i , Heatmaps and metaplots showing the mean Menin signal at promoters in OCI-AML3 cells (ChIP-seq) and one primary patient sample (ChIPmentation), clustered by Menin signal in OCI-AML3 cells.
    Testosterone E El R0389, supplied by Elabscience Biotechnology, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/testosterone e el r0389/product/Elabscience Biotechnology
    Average 94 stars, based on 1 article reviews
    testosterone e el r0389 - by Bioz Stars, 2026-05
    94/100 stars
      Buy from Supplier

    94
    Elabscience Biotechnology activin a
    Dose-dependent effects of ADR administration on circulating reproductive hormones: A) high-dose ADR significantly decreased LH versus control/sham, B) FSH levels remained unchanged across all groups, C) testosterone concentrations were significantly elevated following high-dose ADR treatment, D) <t>activin</t> <t>A</t> levels demonstrated a significant reduction in the high-dose ADR group, E) inhibin B levels significantly increased in the high-dose ADR group. Data are presented as mean ± SD with individual data points (n = 8 per group). One-way ANOVA with Bonferroni-adjusted omnibus α = 0.006 (0.05/8); Tukey’s HSD pairwise comparisons are reported only when the corresponding omnibus test met this adjusted threshold. *p < 0.001 vs. control; #p < 0.001 vs. sham. “ns” over a bracket denotes a nonsignificant Tukey comparison (p ≥ 0.05). Horizontal lines above bars indicate significant pairwise comparisons.
    Activin A, supplied by Elabscience Biotechnology, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/activin a/product/Elabscience Biotechnology
    Average 94 stars, based on 1 article reviews
    activin a - by Bioz Stars, 2026-05
    94/100 stars
      Buy from Supplier

    93
    MedChemExpress acv
    ( A ) Succinct overview of PRV quiescent infection in N2a cells. ( B ) Fluorescence microscopy images depicting N2a cells infected with different doses of HuBXY/2018-mCherry with or without <t>ACV</t> <t>and</t> <t>IFN-α</t> treatments. The images were acquired on 8 dpi. ( C ) Fluorescence intensity of N2a cells infected with different doses of HuBXY/2018-mCherry with or without ACV and IFN-α treatments. ( D ) LAT transcript levels in N2a cells after establishing quiescent infection with HuBXY/2018-mCherry at 0.01 and 0.005 MOI. ( E ) Relative mRNA transcription levels of the early genes IE180 and the LAT in N2a cells after establishing quiescent infection with HuBXY/2018-mCherry at 0.01 MOI (694× indicates that LAT transcription levels are approximately 694-fold higher than those of IE180 transcription). These levels were normalized to the internal reference gene 28 S RNA and calculated using the 2 -ΔΔCt method (Livak method). ( F to I ) Fluorescence microscopy images obtained from HuBXY/2018-mCherry quiescent cells infected with G. parasuis –CF7066, G. parasuis –Nagasaki, and G. parasuis –SH0165 (F); S. suis –SC19, S. suis –P1/7, and S. suis –43 (G); ETEC- C83549 , ETEC-E66, and ETEC-10667 (H); and ExPEC-RS218, ExPEC-PCN033, and medium control (I). Scale bars, 100 μm. All data were analyzed using t test; *** P < 0.001 indicates significant differences.
    Acv, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/acv/product/MedChemExpress
    Average 93 stars, based on 1 article reviews
    acv - by Bioz Stars, 2026-05
    93/100 stars
      Buy from Supplier

    86
    Pfizer Inc acv
    ( A ) Succinct overview of PRV quiescent infection in N2a cells. ( B ) Fluorescence microscopy images depicting N2a cells infected with different doses of HuBXY/2018-mCherry with or without <t>ACV</t> <t>and</t> <t>IFN-α</t> treatments. The images were acquired on 8 dpi. ( C ) Fluorescence intensity of N2a cells infected with different doses of HuBXY/2018-mCherry with or without ACV and IFN-α treatments. ( D ) LAT transcript levels in N2a cells after establishing quiescent infection with HuBXY/2018-mCherry at 0.01 and 0.005 MOI. ( E ) Relative mRNA transcription levels of the early genes IE180 and the LAT in N2a cells after establishing quiescent infection with HuBXY/2018-mCherry at 0.01 MOI (694× indicates that LAT transcription levels are approximately 694-fold higher than those of IE180 transcription). These levels were normalized to the internal reference gene 28 S RNA and calculated using the 2 -ΔΔCt method (Livak method). ( F to I ) Fluorescence microscopy images obtained from HuBXY/2018-mCherry quiescent cells infected with G. parasuis –CF7066, G. parasuis –Nagasaki, and G. parasuis –SH0165 (F); S. suis –SC19, S. suis –P1/7, and S. suis –43 (G); ETEC- C83549 , ETEC-E66, and ETEC-10667 (H); and ExPEC-RS218, ExPEC-PCN033, and medium control (I). Scale bars, 100 μm. All data were analyzed using t test; *** P < 0.001 indicates significant differences.
    Acv, supplied by Pfizer Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/acv/product/Pfizer Inc
    Average 86 stars, based on 1 article reviews
    acv - by Bioz Stars, 2026-05
    86/100 stars
      Buy from Supplier

    Image Search Results


    a , Menin ChIP-seq after 24 h treatment with DMSO or 250 nM Menin inhibitor VTP50469 (MENi) in SEM, RCH-ACV and OCI-AML3 cells. Metaplots show mean reference normalized reads per million (RRPM) centered on transcription start sites (TSS) genome-wide. b , Dose response curves to MENi recorded at 48 h using CellTiterGlo (n = 5 for SEM and RCH-ACV cells, n = 3 for OCI-AML3 cells). c , Colony forming units recorded after culture in Menin inhibitor (n=5). Error bars represent standard error. d , Violin plots depicting the log2 fold changes of differentially expressed genes (FDR < 0.05) after 24 h MENi (250 nM), split by Menin binding at the promoter. e , Upset plot representing the cell lines in which shared Menin-bound genes (centre of Venn diagram in ) are downregulated following MENi (250 nM) for 24 h. f , Intersections of all upregulated genes following 24 h MENi (250 nM) in SEM, OCI-AML3, and RCH-ACV cells. g , Correlation heatmap of genome-wide Menin ChIP-seq signal in cell lines (SEM, RCH-ACV, and OCI-AML3) and Menin ChIPmentation in primary patient samples (NPM1c-AML, iALL28349, iALL863388). h , Heatmaps and metaplots showing the mean Menin signal at promoters in SEM cells (ChIP-seq) and two primary patient samples (ChIPmentation), sorted and k-means clustered by Menin signal in SEM cells. i , Heatmaps and metaplots showing the mean Menin signal at promoters in OCI-AML3 cells (ChIP-seq) and one primary patient sample (ChIPmentation), clustered by Menin signal in OCI-AML3 cells.

    Journal: bioRxiv

    Article Title: Menin maintains enhancer-promoter interactions in a leukemia-specific manner

    doi: 10.64898/2026.01.16.698179

    Figure Lengend Snippet: a , Menin ChIP-seq after 24 h treatment with DMSO or 250 nM Menin inhibitor VTP50469 (MENi) in SEM, RCH-ACV and OCI-AML3 cells. Metaplots show mean reference normalized reads per million (RRPM) centered on transcription start sites (TSS) genome-wide. b , Dose response curves to MENi recorded at 48 h using CellTiterGlo (n = 5 for SEM and RCH-ACV cells, n = 3 for OCI-AML3 cells). c , Colony forming units recorded after culture in Menin inhibitor (n=5). Error bars represent standard error. d , Violin plots depicting the log2 fold changes of differentially expressed genes (FDR < 0.05) after 24 h MENi (250 nM), split by Menin binding at the promoter. e , Upset plot representing the cell lines in which shared Menin-bound genes (centre of Venn diagram in ) are downregulated following MENi (250 nM) for 24 h. f , Intersections of all upregulated genes following 24 h MENi (250 nM) in SEM, OCI-AML3, and RCH-ACV cells. g , Correlation heatmap of genome-wide Menin ChIP-seq signal in cell lines (SEM, RCH-ACV, and OCI-AML3) and Menin ChIPmentation in primary patient samples (NPM1c-AML, iALL28349, iALL863388). h , Heatmaps and metaplots showing the mean Menin signal at promoters in SEM cells (ChIP-seq) and two primary patient samples (ChIPmentation), sorted and k-means clustered by Menin signal in SEM cells. i , Heatmaps and metaplots showing the mean Menin signal at promoters in OCI-AML3 cells (ChIP-seq) and one primary patient sample (ChIPmentation), clustered by Menin signal in OCI-AML3 cells.

    Article Snippet: RCH-ACV and OCI-AML3 (DSMZ) cells were grown in RPMI supplemented with 10% FBS and 1X GlutaMax (Gibco).

    Techniques: ChIP-sequencing, Genome Wide, Binding Assay

    a , Volcano plots of transient transcriptome RNA-seq after 24 h of treatment with DMSO or 250 nM Menin inhibitor VTP50469. b , Mean Menin binding (RRPM = reference normalised ChIP-seq reads per million) in SEM, RCH-ACV, and OCI-AML3 cells at promoters of differentially expressed genes in control (DMSO) or Menin inhibitor treatment (MENi). c , Proportion of differentially expressed genes (n.s. = not significant) following MENi with Menin binding at the promoter (± 2 kb around the TSS). Reported p -values are from a Pearson chi-square test. d , Intersections of all Menin-bound genes in the cell line panel. e , Intersections of downregulated Menin target genes in the cell line panel. f , Examples of Menin ChIP-seq in cell lines (SEM, RCH-ACV, and OCI-AML3) and ChIPmentation in primary patient samples (NPM1c-AML, iALL28349, and iALL863388) at down-regulated genes after 24 h MENi in the indicated cell lines.

    Journal: bioRxiv

    Article Title: Menin maintains enhancer-promoter interactions in a leukemia-specific manner

    doi: 10.64898/2026.01.16.698179

    Figure Lengend Snippet: a , Volcano plots of transient transcriptome RNA-seq after 24 h of treatment with DMSO or 250 nM Menin inhibitor VTP50469. b , Mean Menin binding (RRPM = reference normalised ChIP-seq reads per million) in SEM, RCH-ACV, and OCI-AML3 cells at promoters of differentially expressed genes in control (DMSO) or Menin inhibitor treatment (MENi). c , Proportion of differentially expressed genes (n.s. = not significant) following MENi with Menin binding at the promoter (± 2 kb around the TSS). Reported p -values are from a Pearson chi-square test. d , Intersections of all Menin-bound genes in the cell line panel. e , Intersections of downregulated Menin target genes in the cell line panel. f , Examples of Menin ChIP-seq in cell lines (SEM, RCH-ACV, and OCI-AML3) and ChIPmentation in primary patient samples (NPM1c-AML, iALL28349, and iALL863388) at down-regulated genes after 24 h MENi in the indicated cell lines.

    Article Snippet: RCH-ACV and OCI-AML3 (DSMZ) cells were grown in RPMI supplemented with 10% FBS and 1X GlutaMax (Gibco).

    Techniques: RNA Sequencing, Binding Assay, ChIP-sequencing, Control

    a , UpSet plot representing significantly enriched proteins (FDR < 0.01 compared to IgG controls) co-immunoprecipitated with Menin in SEM, OCI-AML3, and RCH-ACV cells. b , Heatmap of statistically enriched Menin interactors in SEM, RCH-ACV and OCI-AML3 cells. c , Global enrichment of select complexes involved in transcription in Menin co-immunoprecipitations. d , Correlation between the gene effect scores reported in DepMap for SEM and OCI-AML3 CRISPR screens. Proteins within complexes specifically enriched in SEM cells are colored. Genes with an effect score of < -1 in both cell lines are labelled.

    Journal: bioRxiv

    Article Title: Menin maintains enhancer-promoter interactions in a leukemia-specific manner

    doi: 10.64898/2026.01.16.698179

    Figure Lengend Snippet: a , UpSet plot representing significantly enriched proteins (FDR < 0.01 compared to IgG controls) co-immunoprecipitated with Menin in SEM, OCI-AML3, and RCH-ACV cells. b , Heatmap of statistically enriched Menin interactors in SEM, RCH-ACV and OCI-AML3 cells. c , Global enrichment of select complexes involved in transcription in Menin co-immunoprecipitations. d , Correlation between the gene effect scores reported in DepMap for SEM and OCI-AML3 CRISPR screens. Proteins within complexes specifically enriched in SEM cells are colored. Genes with an effect score of < -1 in both cell lines are labelled.

    Article Snippet: RCH-ACV and OCI-AML3 (DSMZ) cells were grown in RPMI supplemented with 10% FBS and 1X GlutaMax (Gibco).

    Techniques: Immunoprecipitation, CRISPR

    a , Pearson correlations between nuclear proteome samples (left) and Menin immunoprecipitation (IP) samples (right), computed on log2-transofrmed and imputed data. b , Correlation in the abundance of differentially enriched complex components in the nuclear proteomes of SEM and OCI-AML3 cells. The grey dashed line represents a slope of 1. Pearson R values are shown for each complex. c , Comparison of proteins enriched in Menin IPs in SEM versus RCH-ACV cells (left) and SEM versus OCI-AML3 cells (right). Only proteins that were statistically enriched over IgG controls in at least one cell line (FDR < 0.01) were included.

    Journal: bioRxiv

    Article Title: Menin maintains enhancer-promoter interactions in a leukemia-specific manner

    doi: 10.64898/2026.01.16.698179

    Figure Lengend Snippet: a , Pearson correlations between nuclear proteome samples (left) and Menin immunoprecipitation (IP) samples (right), computed on log2-transofrmed and imputed data. b , Correlation in the abundance of differentially enriched complex components in the nuclear proteomes of SEM and OCI-AML3 cells. The grey dashed line represents a slope of 1. Pearson R values are shown for each complex. c , Comparison of proteins enriched in Menin IPs in SEM versus RCH-ACV cells (left) and SEM versus OCI-AML3 cells (right). Only proteins that were statistically enriched over IgG controls in at least one cell line (FDR < 0.01) were included.

    Article Snippet: RCH-ACV and OCI-AML3 (DSMZ) cells were grown in RPMI supplemented with 10% FBS and 1X GlutaMax (Gibco).

    Techniques: Immunoprecipitation, Comparison

    a , Heatmaps of Menin ChIP-seq at promoters and enhancers in SEM, RCH-ACV, and OCI-AML3 cells. Regions are sorted by H3K27ac signal and centered on ATAC peaks. b , Heatmaps of Menin ChIPmentation at promoters and enhancers, centred on H3K27ac peaks, in primary samples from two infant MLL-AF4 ALL patients (iALL28349, iALL863388) and one adult NPM1-mutated AML patient. c , Association between Menin binding at intragenic enhancers and differential gene expression from the nearest TSS following 24 h of MENi. p -values are reported from a Pearson chi-square test. d , Mean Menin, MLL/MLL-AF4, and H3K27ac at intragenic enhancers annotated to differentially expressed genes by nearest TSS after 24 h of MENi in SEM and OCI-AML3 cells.

    Journal: bioRxiv

    Article Title: Menin maintains enhancer-promoter interactions in a leukemia-specific manner

    doi: 10.64898/2026.01.16.698179

    Figure Lengend Snippet: a , Heatmaps of Menin ChIP-seq at promoters and enhancers in SEM, RCH-ACV, and OCI-AML3 cells. Regions are sorted by H3K27ac signal and centered on ATAC peaks. b , Heatmaps of Menin ChIPmentation at promoters and enhancers, centred on H3K27ac peaks, in primary samples from two infant MLL-AF4 ALL patients (iALL28349, iALL863388) and one adult NPM1-mutated AML patient. c , Association between Menin binding at intragenic enhancers and differential gene expression from the nearest TSS following 24 h of MENi. p -values are reported from a Pearson chi-square test. d , Mean Menin, MLL/MLL-AF4, and H3K27ac at intragenic enhancers annotated to differentially expressed genes by nearest TSS after 24 h of MENi in SEM and OCI-AML3 cells.

    Article Snippet: RCH-ACV and OCI-AML3 (DSMZ) cells were grown in RPMI supplemented with 10% FBS and 1X GlutaMax (Gibco).

    Techniques: ChIP-sequencing, Binding Assay, Gene Expression

    Dose-dependent effects of ADR administration on circulating reproductive hormones: A) high-dose ADR significantly decreased LH versus control/sham, B) FSH levels remained unchanged across all groups, C) testosterone concentrations were significantly elevated following high-dose ADR treatment, D) activin A levels demonstrated a significant reduction in the high-dose ADR group, E) inhibin B levels significantly increased in the high-dose ADR group. Data are presented as mean ± SD with individual data points (n = 8 per group). One-way ANOVA with Bonferroni-adjusted omnibus α = 0.006 (0.05/8); Tukey’s HSD pairwise comparisons are reported only when the corresponding omnibus test met this adjusted threshold. *p < 0.001 vs. control; #p < 0.001 vs. sham. “ns” over a bracket denotes a nonsignificant Tukey comparison (p ≥ 0.05). Horizontal lines above bars indicate significant pairwise comparisons.

    Journal: Turkish Journal of Medical Sciences

    Article Title: Neuroendocrine effects of exogenous adropin administration on the hypothalamic pituitary testicular axis in male rats

    doi: 10.55730/1300-0144.6164

    Figure Lengend Snippet: Dose-dependent effects of ADR administration on circulating reproductive hormones: A) high-dose ADR significantly decreased LH versus control/sham, B) FSH levels remained unchanged across all groups, C) testosterone concentrations were significantly elevated following high-dose ADR treatment, D) activin A levels demonstrated a significant reduction in the high-dose ADR group, E) inhibin B levels significantly increased in the high-dose ADR group. Data are presented as mean ± SD with individual data points (n = 8 per group). One-way ANOVA with Bonferroni-adjusted omnibus α = 0.006 (0.05/8); Tukey’s HSD pairwise comparisons are reported only when the corresponding omnibus test met this adjusted threshold. *p < 0.001 vs. control; #p < 0.001 vs. sham. “ns” over a bracket denotes a nonsignificant Tukey comparison (p ≥ 0.05). Horizontal lines above bars indicate significant pairwise comparisons.

    Article Snippet: The measurements were carried out using LH (catalog no. E-EL-R0026), FSH (catalog no. E-EL-R0391), testosterone (catalog no. E-EL-R0389), inhibin B (catalog no. E-EL-R0521), and activin A (catalog no. E-EL-R0001), Elabscience, Beijing, China, commercial ELISA kits in accordance with the manufacturer’s instructions.

    Techniques: Control, Comparison

    ( A ) Succinct overview of PRV quiescent infection in N2a cells. ( B ) Fluorescence microscopy images depicting N2a cells infected with different doses of HuBXY/2018-mCherry with or without ACV and IFN-α treatments. The images were acquired on 8 dpi. ( C ) Fluorescence intensity of N2a cells infected with different doses of HuBXY/2018-mCherry with or without ACV and IFN-α treatments. ( D ) LAT transcript levels in N2a cells after establishing quiescent infection with HuBXY/2018-mCherry at 0.01 and 0.005 MOI. ( E ) Relative mRNA transcription levels of the early genes IE180 and the LAT in N2a cells after establishing quiescent infection with HuBXY/2018-mCherry at 0.01 MOI (694× indicates that LAT transcription levels are approximately 694-fold higher than those of IE180 transcription). These levels were normalized to the internal reference gene 28 S RNA and calculated using the 2 -ΔΔCt method (Livak method). ( F to I ) Fluorescence microscopy images obtained from HuBXY/2018-mCherry quiescent cells infected with G. parasuis –CF7066, G. parasuis –Nagasaki, and G. parasuis –SH0165 (F); S. suis –SC19, S. suis –P1/7, and S. suis –43 (G); ETEC- C83549 , ETEC-E66, and ETEC-10667 (H); and ExPEC-RS218, ExPEC-PCN033, and medium control (I). Scale bars, 100 μm. All data were analyzed using t test; *** P < 0.001 indicates significant differences.

    Journal: Science Advances

    Article Title: Transition of pseudorabies virus from latency to reactivation state selectively triggered by pathogenic bacteria

    doi: 10.1126/sciadv.adw4206

    Figure Lengend Snippet: ( A ) Succinct overview of PRV quiescent infection in N2a cells. ( B ) Fluorescence microscopy images depicting N2a cells infected with different doses of HuBXY/2018-mCherry with or without ACV and IFN-α treatments. The images were acquired on 8 dpi. ( C ) Fluorescence intensity of N2a cells infected with different doses of HuBXY/2018-mCherry with or without ACV and IFN-α treatments. ( D ) LAT transcript levels in N2a cells after establishing quiescent infection with HuBXY/2018-mCherry at 0.01 and 0.005 MOI. ( E ) Relative mRNA transcription levels of the early genes IE180 and the LAT in N2a cells after establishing quiescent infection with HuBXY/2018-mCherry at 0.01 MOI (694× indicates that LAT transcription levels are approximately 694-fold higher than those of IE180 transcription). These levels were normalized to the internal reference gene 28 S RNA and calculated using the 2 -ΔΔCt method (Livak method). ( F to I ) Fluorescence microscopy images obtained from HuBXY/2018-mCherry quiescent cells infected with G. parasuis –CF7066, G. parasuis –Nagasaki, and G. parasuis –SH0165 (F); S. suis –SC19, S. suis –P1/7, and S. suis –43 (G); ETEC- C83549 , ETEC-E66, and ETEC-10667 (H); and ExPEC-RS218, ExPEC-PCN033, and medium control (I). Scale bars, 100 μm. All data were analyzed using t test; *** P < 0.001 indicates significant differences.

    Article Snippet: Subsequently, the infective medium was removed, and the infected cells were cultured in a medium containing ACV (MedChemExpress, NJ, USA) and IFN-α2a human recombinant (IFN-α, PROSPEC, Rehovot, Israel) for 8 days.

    Techniques: Infection, Fluorescence, Microscopy, Control

    ( A ) Differentially expressed genes in N2a cells upon ExPEC-induced reactivation of quiescent HuBXY/2018-mCherry. ( B ) Read counts and qPCR validation of CXCL1 transcriptional alteration. ( C ) mRNA transcriptional changes of CXCL1 in N2a cells during ExPEC-induced HuBXY/2018-mCherry reactivation. Data were analyzed using the 2 −ΔΔ C t method. ( D ) CXCL1 transcript levels in each group at 6 and 96 hpi. Data were analyzed using the 2 −ΔΔ C t method. ( E ) Differential transcription of IE180 and LAT in N2a-WT and CXCL1 -KO cells during establishment of HuBXY/2018-mCherry quiescence. ( F ) Fluorescence microscopy and bright-field imaging confirmed ExPEC-induced reactivation of quiescent HuBXY/2018-mCherry in N2a-WT cells, but no reactivation was observed in CXCL1 -KO cells. mCherry fluorescence indicates reactivated HuBXY/2018-mCherry within cells. Scale bar, 100 μm. ( G ) Quantification of HuBXY/2018-mCherry reactivation in N2a-WT and CXCL1 -KO cells by gE copy number ( n = 6). ( H ) Proliferation of HuBXY/2018-mCherry during quiescent infection (ACV + IFN-α) in N2a-WT and CXCL1 -KO cells, assessed by qPCR of gE genome copies. Infected cells were sampled from 0 to 11 dpi. Analyses were performed using t-test (** P < 0.01; *** P < 0.001; ns, P > 0.05). ( I ) Proliferation of HuBXY/2018-mCherry during natural infection in N2a-WT and CXCL1 -KO cells. Samples were collected from 0 to 11 dpi. Analyses were performed using t test (*** P < 0.001; ns, P > 0.05). ( J ) Effect of pEGFP-CXCL1 and pEGFP-vector on HuBXY/2018-mCherry reactivation in CXCL1 -KO cells. Scale bar, 100 μm. ( K ) Quantification of HuBXY/2018-mCherry gE copies in CXCL1 -KO cells transfected with pEGFP-CXCL1 or pEGFP-vector. Analyses were performed using t test (*** P < 0.001; ns, P > 0.05).

    Journal: Science Advances

    Article Title: Transition of pseudorabies virus from latency to reactivation state selectively triggered by pathogenic bacteria

    doi: 10.1126/sciadv.adw4206

    Figure Lengend Snippet: ( A ) Differentially expressed genes in N2a cells upon ExPEC-induced reactivation of quiescent HuBXY/2018-mCherry. ( B ) Read counts and qPCR validation of CXCL1 transcriptional alteration. ( C ) mRNA transcriptional changes of CXCL1 in N2a cells during ExPEC-induced HuBXY/2018-mCherry reactivation. Data were analyzed using the 2 −ΔΔ C t method. ( D ) CXCL1 transcript levels in each group at 6 and 96 hpi. Data were analyzed using the 2 −ΔΔ C t method. ( E ) Differential transcription of IE180 and LAT in N2a-WT and CXCL1 -KO cells during establishment of HuBXY/2018-mCherry quiescence. ( F ) Fluorescence microscopy and bright-field imaging confirmed ExPEC-induced reactivation of quiescent HuBXY/2018-mCherry in N2a-WT cells, but no reactivation was observed in CXCL1 -KO cells. mCherry fluorescence indicates reactivated HuBXY/2018-mCherry within cells. Scale bar, 100 μm. ( G ) Quantification of HuBXY/2018-mCherry reactivation in N2a-WT and CXCL1 -KO cells by gE copy number ( n = 6). ( H ) Proliferation of HuBXY/2018-mCherry during quiescent infection (ACV + IFN-α) in N2a-WT and CXCL1 -KO cells, assessed by qPCR of gE genome copies. Infected cells were sampled from 0 to 11 dpi. Analyses were performed using t-test (** P < 0.01; *** P < 0.001; ns, P > 0.05). ( I ) Proliferation of HuBXY/2018-mCherry during natural infection in N2a-WT and CXCL1 -KO cells. Samples were collected from 0 to 11 dpi. Analyses were performed using t test (*** P < 0.001; ns, P > 0.05). ( J ) Effect of pEGFP-CXCL1 and pEGFP-vector on HuBXY/2018-mCherry reactivation in CXCL1 -KO cells. Scale bar, 100 μm. ( K ) Quantification of HuBXY/2018-mCherry gE copies in CXCL1 -KO cells transfected with pEGFP-CXCL1 or pEGFP-vector. Analyses were performed using t test (*** P < 0.001; ns, P > 0.05).

    Article Snippet: Subsequently, the infective medium was removed, and the infected cells were cultured in a medium containing ACV (MedChemExpress, NJ, USA) and IFN-α2a human recombinant (IFN-α, PROSPEC, Rehovot, Israel) for 8 days.

    Techniques: Biomarker Discovery, Fluorescence, Microscopy, Imaging, Infection, Plasmid Preparation, Transfection